Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3
| العنوان: | Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3 |
|---|---|
| المؤلفون: | Ulrik Nilesen, Lihui Xu, Neeraj Kohli, Alexey Lugovskoy, Jonathan Fitzgerald, Jian Tang, Jason Baum, Yang Jiao, Bryan Johnson, Rachel Rennard, Sharlene Adams |
| المصدر: | Molecular Cancer Therapeutics. 10:B205-B205 |
| بيانات النشر: | American Association for Cancer Research (AACR), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Cancer Research, business.industry, medicine.drug_class, Growth factor, medicine.medical_treatment, Cancer, Pharmacology, medicine.disease, Monoclonal antibody, Oncology, DU145, Pancreatic cancer, Neuregulin, Medicine, ERBB3, business, Protein kinase B |
| الوصف: | Monoclonal antibodies have significantly advanced our ability to treat cancer, but most patients do not have durable responses to therapy. We find that the majority of tumor cell lines are responsive to activation by two or more growth factors. In particular cell lines grown in culture and in mice appear to frequently rely on Insulin-like growth factor 1 (IGF-1) and Heregulin (HRG) signaling to redundantly support their proliferation. Using a Network Biology approach, we have designed, constructed and optimized a novel bispecific antibody, MM-141, for simultaneous targeting and inhibition of ErbB3 and IGF-1R. MM-141 blocks IGF-1, IGF-2, and heregulin-induced AKT signaling, inhibits growth of multiple cancer cell lines, and is active in xenograft models of human pancreatic cancer (BxPC-3) and human prostate cancer (DU145). MM-141 does not bind the insulin receptor, thus strongly reducing the risk of metabolic side effects. MM-141 has favorable CMC and pharmacokinetic profiles and is being advanced into preclinical development. Taken together, these results suggest that MM-141 has the potential to be an effective therapeutic for treatment of patients with solid tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B205. |
| تدمد: | 1538-8514 1535-7163 |
| DOI: | 10.1158/1535-7163.targ-11-b205 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::70d127a49bf919435ae466b17fdea3e5 https://doi.org/10.1158/1535-7163.targ-11-b205 |
| رقم الانضمام: | edsair.doi...........70d127a49bf919435ae466b17fdea3e5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15388514 15357163 |
|---|---|
| DOI: | 10.1158/1535-7163.targ-11-b205 |